Page 23 - Read Online

Wu et al. Cancer Drug Resist 2018;1:204-18 I http://dx.doi.org/10.20517/cdr.2018.16 Page 215

Oncology, Merck-Serono and honorarium from Eli-Lilly.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Moek KL, de Groot DJA, de Vries EGE, Fehrmann RSN. The antibody-drug conjugate target landscape across a broad range of tumour
types. Ann Oncol 2017;28:3083-91.
3. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev
Drug Discov 2017;16:315-37.
4. Lambert JM, Morris CQ. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther
2017;34:1015-35.
5. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic
anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-7.
6. Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2012;11:19-20.
7. Lambert JM, Chari RV. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J
Med Chem 2014;57:6949-64.
8. Yamaguchi M, Hirose K, Hirai N. HER2 expression in gastrointestinal carcinoid tumors: high in intestinal but not in gastric tumors.
Surg Today 2007;37:270-1.
9. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol
2012;25:63750.
10. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-
label, randomised controlled trial. Lancet 2010;376:687-97.
11. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given
every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704.
12. Beeram M, Krop IE, Burris HA, Girish SR, Yu W, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in
patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 2012;118:5733-40.
13. Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, et al. Relationship between tumor biomarkers and efficacy in EMILIA, a phase
III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res 2016;22:3755-63.
14. Kim SB, Wildiers H, Krop IE, Smitt M, Yu R, et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III
study of trastuzumab emtansine (T-DM1) vs. treatment of physician’s choice in previously treated HER2-positive advanced breast
cancer. Int J Cancer 2016;139:2336-42.
15. Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, et al. Trastuzumab emtansine versus taxane use for previously treated
HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international
randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 2017;18:640-53.
16. Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, et al. A phase II trial of vinorelbine in patients with advanced
gastroesophageal adenocarcinoma. Cancer Invest 2006;24:346-50.
17. Peng Z, Zou J, Zhang X, Yang Y, Gao J, et al. HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis.
Chin J Cancer Res 2015;27:163-71.
18. Janjigian YY, Riches JC, Ku GY, Imtiaz T, Capanu M, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in
HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab. J Clin Oncol 2015;33:63.
19. Ishimine Y, Goto A, Watanabe Y, Yajima H, Nakagaki S, et al. Loss of HER2 positivity after trastuzumab in HER2-positive gastric
cancer: is change in HER2 status significantly frequent? Case Rep Gastrointest Med 2015;2015:132030.
20. Seo S, Ryu MH, Ahn JY, Park Y, Park SR, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric
cancer patients: results of GASTric cancer HER2 reassessment study 3 (GASTHER3). J Clin Oncol 2017;35:27.
21. Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, et al. Genetic predictors of response to systemic therapy in
esophagogastric cancer. Cancer Discov 2018;8:49-58.
22. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, et al. Antibody-maytansinoid conjugates are activated in targeted